合并阻塞性睡眠呼吸暂停低通气综合征的急性冠脉综合征病人的临床特点分析被引量：3

导出

摘要目的探讨合并阻塞性睡眠呼吸暂停低通气综合征(OSAHS)的急性冠脉综合征(ACS)病人的临床特点并分析其预后。方法 56例合并OSAHS的ACS病人为研究组,并有91例不合并OSAHS的ACS病人作观察组,75例正常健康体检者为对照组。观察各组的临床特征、住院期间研究组与观察组恶性心脏事件、冠脉造影情况及研究组一年随访情况。结果与对照组、观察组比较,研究组体重指数、血C反应蛋白明显增高,合并糖代谢、脂代谢异常、合并高血压病、周围动脉粥样硬化症病人比例明显增高(P<0.01)。与观察组比较,研究组住院期间恶性心脏事件(猝死、危及生命的心律失常、休克)增高,冠脉造影阳性率增高及多支冠状动脉病变增多;研究组随访一年,无创呼吸机干预37例,2例有再发心脏事件;失访1例;未呼吸机干预18例,再发心脏事件7例(其中心脏猝死1例)。结论合并OSAHS的ACS病人合并冠心病危险因素明显增加,尤其C反应蛋白明显增高;在住院期间死亡风险明显增加且冠脉病变阳性率及3支病变增加。积极无创呼吸机干预远期预后好。

作者李福娥张桂英杨晋任永林刘亚楠安旭峰

机构地区山西阳煤集团总医院

出处《中西医结合心脑血管病杂志》 2012年第12期1509-1510,共2页 Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease

关键词阻塞性睡眠呼吸暂停低通气综合征急性冠脉综合征心脏事件

分类号 R541.4 [医药卫生—心血管疾病] R256.2 [医药卫生—中医内科学]

引文网络
相关文献

参考文献7

1中华医学会呼吸病学分会睡眠呼吸疾病学组.阻塞性睡眠呼吸暂停低通气综合征诊治指南(草案)[J].中华结核和呼吸杂志,2002,25(4):195-198. 被引量：1851
2Arters J L, Chi DS, Girish M, et al. Obstructive sleep apnea, inflam- mation, and cardiopulmonary disease [ J ]. Front Biosci, 2004, 9 : 2892 - 2900.
3Shamsuzzaman AS, Winnicki M, Lanfranchi P,et al. Elevated C- reactive protein in patients with obstructive sleep apnea[J]. Circu lation,2002,105(21) :2462 - 2464.
4Yokoe T, minoguchi K, Matsuo H, eZ al. Elevated levels of C - re active protein and Interleukin - 6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure[J]. Circulation,2003,107(8) :1129 - 1134.
5Maekawa M, Shiomi T, Usui K, et al. Prevalence of ischemic heart disease among patients with sleep apnea syndrome[J]. Psychiatry Clin Neurosci, 1998,52(2) : 219 - 220.
6Haught WH, Mansour M,Rothlein R, et al. Alteration on circulat- ing intercellular adhesion molecule - 1 and L - selectin further evi dence for chronic inflammation in ischemic heart disease[J]. Am Heart J,1996,132(1) 1 - 6.
7刘蓉,杨跃进,乔树宾,陈纪林,陈在嘉,高润霖,吴元,杨伟宪,赵冬云.高敏C反应蛋白对急性ST段抬高型心肌梗死患者近期预后的预测价值[J].中国循环杂志,2011,26(1):19-22. 被引量：70

二级参考文献12

1Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation ,2002,105 : 1135-1143.
2Mendall MA, Strachan DP, Butland BK, et al. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J,2000,21:1584-1590.
3Schnabel R, Rupprecht HJ, Lackner KJ, et al. Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene study. Eur Heart J,2005,26:241-249.
4Tommasi S, Carluccio E, Bentivoglio M, et al. C-reactive protein as a marker for cardiac ischemic events in the year after a first, uncomplicated myocardial infarction. Am J Cardiol, 1999,83 : 1595-1599.
5Mega JL, Morrow DA, De Lemos JA, et al. B-type natfiuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction : an ENTIRE-TIMI-23 substudy. J Am Coll Cardiol, 2004,44:335-339.
6Akkus MN, Polar G, Yurtdas M, et al. Admission levels of C-reac- tive protein and plasminogen activator inhibitor-1 in patients with acute myocardial infarction with and without cardiogenic shock or heart failure on admission. Int Heart J,2009,50:33-45.
7Berton G, Cordiano R, Palmieri R, et al. C-reactive protein in acute myocardial infarction: association with heart failure. Am Heart J, 2003,145 : 1094-1101.
8Scifica BM, Morrow DA, Cannon CP, et al. Clinical application of C-reactive protein across the spectrum of acute coronary syndromes. Clinical Chemistry,2007,53 : 1800-1807.
9Katayama T, Iwasaki Y, Yamamoto T, et al. "Smoker' s paradox" in patients with acute myocardial infarction receiving primary coronary intervention . Cardio1,2006,48 : 193-200.
10Suleiman M, Khatib R, Agmon Y, et al. Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein. J Am Coil Cardio1,2006 ,47 :962-968.